VENN STRATEGIES

Lobbying for UCB, INC. · Biopharmaceutical company dealing in severe diseases in immunology and neurology.

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 17, 2026

Income

$80,000.00

What the client paid this registrant for the period.

Client based in

Georgia

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 2

Health Issues

Policies related to biopharmaceutical access and innovation.

Taxation/Internal Revenue Code

International tax issues and the corporate rate

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.